Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction (CorCinch-HFrEF)
An Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF) - The CorCinch-HFrEF Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University Hospital Midtown
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Louisiana
-
Houma, Louisiana, United States, 70360
- Cardiovascular Institute of the South
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Minneapolis Heart Foundation Institute
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68526
- Nebraska Heart Institute / Nebraska Heart Hospital
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10032
- Columbia University Medical Center/NYPH
-
New York, New York, United States, 10029
- Mt. Sinai
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, United States, 17101
- Pinnacle Health Cardiovascular Institute
-
Hershey, Pennsylvania, United States, 17033
- Penn State Health Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, United States, 77020
- Baylor College of Medicine St. Luke's Medical Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84109
- Intermountain Medical Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia School of Medicine
-
Roanoke, Virginia, United States, 24014
- Carilion Roanoke Memorial
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Study patient is at least 18-years old
- Ejection Fraction: ≥20 and ≤40%
- LV end-diastolic diameter ≥55 mm
- Symptom Status: NYHA III-IV (i.e., ambulatory)
- Treatment and compliance with optimal guideline directed medical and device-based therapies for heart failure (unless contraindicated or intolerant) for at least 3 months and stable doses for 1 month with stable defined as no more than 100% increase or 50% decrease of total daily doses.
- Patients with left bundle branch block pattern and QRS duration >150ms are required to have a CRT device for at least 3 months
- Patients required to have an ICD are required to have ICD implant at least 1 month prior to enrollment
- Able and willing to complete all qualifying diagnostic and functional tests and agrees to comply with study follow-up schedule
Exclusion Criteria:
- Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 3 months
- Mitral regurgitation grade 3 (moderate-severe) or more
- Prior surgical, transcatheter, or percutaneous mitral valve intervention
- Untreated clinically significant coronary artery disease (CAD) requiring revascularization
- Hemodynamic instability: Hypotension (systolic pressure <90 mmHg) or requirement for inotropic support or mechanical hemodynamic support
- Any planned cardiac surgery or interventions within the next 6 months (including right heart procedures)
- NYHA class IV (i.e., non-ambulatory)
- Significant RV dysfunction (TAPSE < 14)
- Severe tricuspid regurgitation
- Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
- Anatomical pathology or constraints preventing appropriate access/implant of the AccuCinch® Ventricular Repair System (e.g., femoral arteries will not support a 20F system)
- Renal insufficiency (i.e., eGFR of <30ml/min/1.73m2; Stage 4 or 5 CKD)
- Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis
- Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation
- Active bacterial endocarditis
- History of any stroke within the prior 3 months or Modified Rankin Scale ≥ 4 disability from any prior stroke
- Subjects in whom anticoagulation or antiplatelet therapy is contraindicated
- Known allergy to nitinol, polyester, or polyethylene
- Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure.
- Life expectancy < 1 year due to non-cardiac conditions
- Currently participating in another interventional investigational study
- Implant or revision of any rhythm management device (CRT or CRT-D) prior 3 months or implantable cardioverter defibrillator within the prior 1 month
- Subjects on high dose steroids or immunosuppressant therapy
- Female subjects who are pregnant, of child bearing potential without a documented birth control method, or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AccuCinch® Ventricular Restoration System
|
AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety measured by device-related or procedure-related major adverse events (MAEs)
Time Frame: 30-day
|
Device-related or procedure-related major adverse events (MAEs)
|
30-day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ulrich Jorde, MD, Montefiore Medical Center
- Principal Investigator: Azeem Latib, MD, Montefiore Medical Center
- Study Director: Michael Zapien, MS, CCRA, Ancora Heart, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 5017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.